You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Clinical Development of a Therapeutic Agent for COPD
SBC: BIOMARCK PHARMACEUTICALS, LTD Topic: NHLBIDESCRIPTION (provided by applicant): Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases, including chronic pulmonary disease (COPD), asthma, cystic fibrosis, allergic rhinitis, and bronchiectasis.Despite the obvious medical importance, there presently are no effective therapies to control excess mucus secretion in these diseases, and very ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Clinical Development of a Therapeutic Agent for COPD
SBC: BIOMARCK PHARMACEUTICALS, LTD Topic: NHLBIDESCRIPTION provided by applicant Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases including chronic pulmonary disease COPD asthma cystic fibrosis allergic rhinitis and bronchiectasis Despite the obvious medical importance there presently are no effective therapies to control excess mucus secretion in these diseases and very ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Photoacoustic CT for Preclinical Molecular Imaging
SBC: OPTOSONICS, INC. Topic: N/ADESCRIPTION (provided by applicant): The long-term objective of this collaborative research project is to commercialize a prototype photoacoustic computed-tomography (PCT) scanner for conducting preclinical molecular imaging. This scanner has been developed by OptoSonics with funding from a Fast Track SBIR grant from the National Cancer Institute (R44-CA-102891) and additional private funding fro ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
Safe and effective anti CD154 antibodies for therapeutic intervention
SBC: Immunext, Inc. Topic: NIAIDDESCRIPTION provided by applicant In both animal proof of concept studies and preliminary clinical trials there is ample data demonstrating the potential therapeutic benefits o CD blockade for treatment of GVHD organ transplantation and autoimmune diseases However development of CD as a therapeutic has been impeded by antibody toxicity observed in early clinical trials GVHD is a ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Novel Manufacturing Processes for Tissue Engineered Vascular Grafts
SBC: HUMACYTE, INC. Topic: NHLBIDESCRIPTION (provided by applicant): This Phase IIB SBIR application is responsive to NHLBI RFA HL-13-016, NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood and Sleep Disorders and Diseases (R44) . This RFA solicits work on basic, applied, and clinical research on all product and service development related to the mission of the NHLBI. ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Novel Manufacturing Processes for Tissue Engineered Vascular Grafts
SBC: HUMACYTE, INC. Topic: NHLBIDESCRIPTION provided by applicant This Phase IIB SBIR application is responsive to NHLBI RFA HL andquot NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart Lung Blood and Sleep Disorders and Diseases R andquot This RFA solicits work on andquot basic applied and clinical research on all product and service development related to the ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Self Assembling High Affinity Peptides for Point of Care Drug-Device Combinations
SBC: AFFINERGY, LLC Topic: N/ADESCRIPTION (provided by applicant): Infection surrounding metal implants is a common and sometimes devastating cause of implant failure in a number of fields including oral, craniomaxillofacial (CMF), orthopedic, and cardiovascular surgery. These infections, which arise from the establishment of biofilms on device surfaces, not only necessitate new surgeries but in themselves present a significan ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
Commercialization of Human Mesothelial Cells for Research
SBC: Zen-Bio, Inc. Topic: N/ADESCRIPTION (provided by applicant): Mesothelial cells have been found to be pivotal in tumor metastasis, peritoneal dialysis, and inflammatory response. These cells are specialized epithelial cells that line the peritoneal, pericardial, and pleural cavities and internal organs presenting a barrier to invading organisms and physical damage. Ovarian tumor attachments occur through cancer cells bind ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
Expanding Precision Particle Fabrication Technology for the Widespread Control of
SBC: ORBIS BIOSCIENCES, INC. Topic: NIBIBDESCRIPTION provided by applicant A critical need currently exists in the pharmaceutical market for microparticles that can accurately and effectively control the release of poorly water soluble compounds Although these poorly water soluble drugs are projected to have high clinical efficacy they are often rejected in the early stages of research because of the high cost and technical difficulties ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Novel Formulations for Injectable Growth Factors
SBC: AFFINERGY, LLC Topic: N/ADESCRIPTION (provided by applicant): Over 6.3 million fractures occur each year in the United States alone (Praemer et al. 1999) and approximately 15% of fractures exhibit delayed or impaired healing. The clinical applications currently used to treat delayed fracture require open surgery to insert an autologous bone graft. If open surgery is confounded by co-morbidity or is deemed otherwise undes ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health